Background. The dynamics of the early stages of West Nile virus (WNV) infection can be assessed by follow-up studies of viremic blood donors.
West Nile virus (WNV) is an important cause of neuroinvasive disease and febrile illness in the United States [1] [2] [3] [4] . In 2002 evidence accumulated that WNV could be transmitted through transfusions [5, 6] , and in June 2003 nucleic acid amplification testing (NAT) of blood donors for WNV RNA was begun [7] .
Donor samples are tested in minipools (MPs) in a fashion similar to that of NAT for HIV-1 and hepatitis C virus [8] . In addition to MP-NAT, blood centers developed strategies to switch to individual donation (ID)-NAT in regions experiencing epidemic WNV activity in order to interdict donations with low-level viremia missed by MP-NAT [9 -14] . These approaches have proven highly effective, interdicting Ͼ2000 viremic donations and nearly eliminating the risk of transfusiontransmitted WNV [10 -16] .
A detailed understanding of the dynamics of the early stages of WNV infection is important for developing algorithms for screening and confirming potentially infected donors, deciding when it is safe for such donors to resume blood donations, and evaluating the residual risk of transfusion-transmitted infection. More generally, an understanding of WNV infection dynamics is important for developing diagnostic testing algorithms and design-ing research protocols to study pathogenesis and immune responses that may influence development or treatment of WNV disease.
Use of sensitive WNV RNA detection assays in donor screening has allowed implementation of several approaches to study these issues. The first approach, developed by our group, involved use of the incidence-window period model to comprehensive NAT and IgM incidence data in North Dakota donors to estimate the interval after infection onset that WNV RNA is detectable by MP-NAT; this so-called MP-NAT window is 6.9 days (95% confidence interval [CI], 3.0 -10.7 days) [13] . By comparing the yields of donors detected by ID-NAT and MP-NAT in the entire Blood Systems donor population over a 2-year period, we were able to further estimate that the length of an even earlier stage of low-level viremia (defined as a detectable level of WNV RNA by ID-NAT but not MP-NAT) is Ͻ1 day [12] .
These approaches, however, are limited for studying later stages of infection after the development of IgM and IgG antibody responses. A cross-sectional analysis is likely to be biased because symptoms are more likely during these stages and because symptomatic individuals either do not attempt to donate or are deferred, owing to elevated temperatures or reports of mild symptoms [17] . Despite these limitations, cross-sectional screening data combined with limited follow-up data have allowed for a general picture of the dynamics of the later stages of WNV infection to emerge. After the initial phase of increasing viremia, viral loads begin to decrease before or concurrent with IgM and IgA antibody development, followed shortly thereafter by development of IgG antibody [11, 12, 18 -22] . However, the precise duration of viremia and its relationship to antibody development and symptoms have not been well-defined [11-14, 18 -22] . Furthermore, available data concerning IgM and IgA persistence are conflicting [18 -22] .
In this study, we use data derived from serial follow-up of a large number of viremic donors and from replicate testing by use of a very sensitive WNV RNA detection system to further define the natural history of viremia and its relationship to the development and persistence of IgM, IgA, and IgG antibodies.
SUBJECTS, MATERIALS, AND METHODS
WNV RNA screening, enrollment, and follow-up of viremic donors. Donations from 19 US blood-collection facilities (in the southwest, south, and central plains and in parts of California) owned by Blood Systems were screened for WNV by means of the WNV transcription-mediated amplification (TMA) system (Procleix WNV Assay [Gen-Probe]) in minipools of 16 samples as previously described [7, 12, 23] . The 16 donations that comprised reactive minipools were tested individually to identify the viremic donation. The TMA WNV assay has an analytical sensitivity of ϳ4 RNA copies/mL (i.e., 50% of the lower limit of detection, according to probit analysis) and a sensitivity of ϳ45 copies/mL when used in MP screening [7, 23] .
All TMA-reactive donors identified in 2003 were offered enrollment into a follow-up study, with return visits scheduled at approximately weekly intervals for the first 4 weeks, followed by monthly visits for up to 3 additional months or until antibody seroconversion. TMA-reactive donors were classified as having confirmed WNV infection if WNV IgM was detected in either the index or follow-up specimens, if WNV RNA was detected in the index donation by repeat WNV TMA screening and confirmed by an alternate NAT assay, or if WNV RNA was found by TMA in a follow-up sample [7, 12, 23] .
The aim of the 2003 study was to investigate viral and antibody dynamics for several weeks after detection of infection (table 1). Follow-up specimens were tested for WNV RNA by TMA and for IgM and IgG WNV-specific antibody (Focus Diagnostics). Persistence of low-level viremia (defined as a WNV RNA level less than the lower limit of ID-TMA detection) was investigated by performing 5 additional replicate ID-TMA assays on all 180 available serial follow-up samples from a subset of 56 subjects in the 2003 donor cohort from whom specimens were collected Ͼ30 days following the index donation.
A similar protocol was followed for confirmed WNV-positive donors identified in 2004, except that an increased focus was placed on persistence of viremia over a longer interval (Ͼ40 days after the index donation); hence, all donors were recalled weekly for 4 weeks and then monthly for 3 months. Because of limitations in the volume of samples, follow-up samples collected Ͻ40 days after the index donation were evaluated by ID-TMA and IgM and IgG enzyme immunoassays (EIAs) but not by replicate TMA. Samples from these earlier visits were used to conduct quantitative viral load and plasma cytokine and chemokine immunoassays; findings are reported elsewhere [24] . All samples collected Ͼ40 days after viremic donations were tested by 6-replicate TMA.
For 2005, the follow-up algorithm was further modified to perform extensive immunological studies to characterize cellular immune response to WNV [25] . Weekly specimens were collected for 1 month, followed by monthly collection of specimens at 2, 3, 6, and 12 months; these longer-term samples were used in the present study to assess the persistence of WNV RNA and IgM, IgA, and IgG antibodies.
For all 3 years, all available serial samples from any donor in whom RNA was detected Ͼ40 days after the index donation were tested for neutralizing antibody by WNV plaque-reduction neutralization testing (PRNT). PRNT was also performed on all serial samples from 23 additional representative cases to compare the time of IgM and IgG seroconversion with development of detectable neutralizing antibody activity.
WNV serologic assays. Plasma specimens were tested for WNV IgM and IgG by use of US Food and Drug Administration (FDA)-licensed enzyme-linked immunosorbent assay (ELISA) kits (Focus Diagnostics). The assays were performed according to instructions in the package inserts [26, 27] . WNV IgA was measured using an in-house alpha-capture ELISA (Focus Diagnostics) modeled after the WNV IgM ELISA.
PRNT assays for WNV and St. Louis encephalitis virus (performed to rule out cross-reactivity) were conducted using Vero cell monolayers in accordance with a standardized protocol developed by the Centers for Disease Control and Prevention [28] . Titers were expressed as the reciprocal of the plasma dilution that reduced or neutralized the challenge inoculum by 90%.
Statistical methods. Actual donor return times varied, resulting in intermittent collection of blood specimens. Because changes in antibody or RNA status would have occurred during the interval between 2 particular donations, interval-censored data methods were used [29] . The median window periods (defined as the intervals between the selected viral RNA thresholds and antibody seroconversion, as well as the times to achievement of undetectable WNV RNA, IgM, and IgG levels) were derived from an accelerated failure time model [30] . The window period distributions were then estimated [31] . The 95th and 99th percentiles (interpreted as inclusion bounds) were derived from the estimated window period distributions.
For purposes of illustration, the index donation (i.e., the donation in which WNV RNA was detected) was assumed to have occurred at the midpoint of the window of RNA detectability. The duration of this window has previously been estimated to be 6.9 days and begins a day or two following incident WNV infection [13] .
We performed regression analysis using several linear mixedeffects models to determine the time at which IgM and IgA EIA seroreversion was detected by EIA. The mixed-effect models account for the multiple measures per donor by estimating random (i.e., separate) slope and intercept effects for each patient and fixed slope and intercept effects for the population represented by the sample of donors. We also chose the logtransformation of both dependent and independent variables (log-log method), as it provided the best data fit and improved conformance to the models' assumptions [32] . The independent variable was the log-transformed EIA sample-to-calibrator ratio (S/C), and the dependent variable was the log-transformed duration after the index visit, restricted to Ͼ21 days in order to model only the descending section of the antibody-response curve. The models were fit to the data by use of the R statistical package [33] .
Human subjects research approval. Donor screening and follow-up testing to establish donors' true infectious status were conducted with the approval of the Western Investigational Review Board. Additional follow-up testing in 2004 and 2005 was approved by the University of California, San Francisco, Committee for Human Research. All donors gave written informed consent for WNV screening and follow-up testing.
RESULTS
Of 292 viremic donors identified by MP-NAT in 2003-2004, a total of 245 (84%) were enrolled in our follow-up studies. These donors contributed a total of 973 specimens that were examined for WNV RNA and antibody (table 1). The durations of various intervals (designated as window periods) were estimated as illustrated in figure 1 and detailed in table 2.
The median window periods from RNA detection to IgM and IgG seroconversion were 3.9 days (95% CI, 3.4 -4.4 days) and 7.7 days (95% CI, 6.9 -8.5 days), respectively. The median time between IgM and IgG seroconversion was 3.4 days (95% CI, Two subset analyses were performed for donors enrolled in 2003. The first evaluated 56 donors for WNV RNA persistence by performing TMA on 6 replicate aliquots from a given study visit. RNA was detectable for an additional 6.1 days (95% CI, 4.2-8.0 days) after results of single-replicate TMA were negative. In the second analysis, PRNT was performed to detect WNV- of the replicate TMA assays were reactive during a given study visit, indicating very low RNA concentrations. In 2 cases, RNA detection was intermittent, with partially reactive replicates separated by WNV RNA-negative specimens. The donor with the longest duration of RNA detection had reactive results on days 57, 83, and 104 after the index donation. PRNT documented WNV-specific neutralizing activity (defined as a titer of Ͼ160) in all RNA-positive and RNA-negative samples collected Ͼ8 days after the index donation in all 4 persistent viremia cases, 2 of which showed IgM seroreversion (table 3, donors 3 and 4).
In 2005, a total of 22 and 13 of 35 enrolled donors were followed up long enough to document complete loss of IgM and IgA, respectively; IgG persisted with no decrease in reactivity in all cases (figures 2 and 3). The mean times to IgM and IgA negativity were 156 days (95% CI, 70 -423 days) and 220 days (95% CI, 48 -2100 days), respectively. A minimum follow-up period of 3 months was achieved for 31 donors (89%), and 23 donors were followed up for the full 12 months. At 12 months, all 23 donors (100%) were IgG positive, 4 (17%) were IgM positive, and 13 (57%) were IgA positive (P ϭ .013, IgA positivity vs. IgM positivity).
DISCUSSION
Our data, combined with previously reported observations, allow us to formulate a comprehensive picture of the dynamics of viremia and antibody production in persons with WNV infection (figure 1). The dynamics of the very earliest phase of infection, defined as the time from a bite by an infected mosquito to the first detectable level of WNV RNA in plasma, are not known. Although viremia is first detectable 1-2 days after inoculation in experimental WNV infection involving immunosuppressed humans and mammalian model systems, it is unclear whether these same time frames are applicable to natural infection in healthy humans [34 -37] . Once viremia becomes detectable by sensitive ID-NAT, there is a very brief period (ϳ1 day) when viremia is detectable only by ID-NAT but is below the limit of detection by MP-NAT. This level of WNV has been demonstrated to transmit infection by the transfusion route, which has led to the implementation of targeted ID-NAT donor screening during epidemics in specific locales [9, 11, 12, 15, 16] .
Viremia is then detectable by MP-NAT for a mean of 6.9 days [13] ; during this period, viral concentrations increase and then decrease below the threshold of MP-NAT detectability, as indicated by 2 independent reports that quantitated viral load in 579 NAT-reactive blood donations [11, 12] . The median viral load was ϳ5 ϫ 10 3 copies/mL for ϳ90% of the MP-NAT-positive donations detected before the development of IgM antibody and was below the limit of quantitation (defined as 50 -100 copies/ mL) for IgM-positive donations [11, 12] .
Our current data establish that IgM antibody becomes detectable a median of 3.9 days after the midpoint of the MP-NAT detection interval (which roughly coincides with the time of peak viremia), with IgM appearance occurring ϳ1 day before viremia decreased to a level below the limit of MP-NAT detection [7, 11, 12, 21, 22, 24] . IgG develops within 3.4 days of IgM detection. Although IgA levels were not directly measured in our 2003 and 2004 cohorts, results from a previous study reported by our group and data from the current 2005 donor cohort (data not shown) indicate that IgA antibody development follows a very similar time course to that of IgM and is consistently detected several days before IgG [22] . Detection of WNV-specific neutralizing antibody activity by PRNT is also approximately coincident with detection of seroconversion by commercially available IgM and IgG EIAs.
In the early stages of antibody development, plasma viremia remains detectable if sensitive NAT assays are used; we detected RNA for an additional 13.2 days by single-replicate ID-TMA and for a further 6.1 days by 6-replicate ID-TMA. In all cases, this "tail-end" viremia was found in association with IgM, IgA, and IgG, including WNV-specific neutralizing antibodies in the 4 cases in which RNA levels persisted for Ͼ40 days. Therefore, if RNA assays with sufficient sensitivity are used, it appears that antibody development generally precedes loss of detectable RNA by several weeks.
The viral and antibody dynamics that we report are influenced by the assays we used. Our antibody assays could not detect antibody in immune complexes, and our RNA assay did not detect cell-associated WNV, which has been demonstrated to occur [38] . To explore these relationships, further studies would be needed.
We previously estimated that IgM and IgA antibodies persist for 218 and 232 days, respectively, by extrapolating the rate of antibody EIA signal loss over time for a set of donors whose follow-up samples were generally obtained 180 days after viremic donations [22] . In the current study, we analyzed a data set that includes follow-up antibody results for 51 specimens from 35 donors that were collected Ͼ180 days after the index donation. We altered the log-linear model we used in the previous study in order to better fit these expanded data. IgM disappeared before IgA (mean times to seroreversion, 156 days for IgM and 220 days for IgA). IgM persisted for Ͼ1 year in 17% of cases; IgA persisted for Ͼ1 year in 57% of cases. This latter finding has important diagnostic implications, because the presence of IgM or IgA is not necessarily indicative of infection during a current- year epidemic; in some cases, these antibodies could represent an immunologic response to WNV infection acquired during the previous mosquito season. We have further established that IgG persists at essentially the same titer (as indicated by stable S/C ratios) for at least 1 year.
Because of the logistics of blood donor testing, it is very difficult to notify and enroll donors within the first several days after a viremic donation. Given rapid viremia development and seroconversion, all studies of these dynamic phenomena in blood donors have several limitations, including the lack of specimens collected at closely spaced intervals immediately after infection, the inability to determine the point in the MP-NAT detection interval during which each donor presented for donation, and intradonor variation in the time of sampling. In this study we used interval-censored data methods [29] , which allowed us to make reasonably precise estimates of the median duration of window periods, associated confidence intervals, and inclusion bounds, akin to other studies [39 -41] .
Our finding that viremia is present for at least 7 days before development of IgM and persists for 9.5 days (95% CI, 7.7-11.3 days) after IgM seroconversion predicts that plasma RNA testing by use of sensitive assays might be useful in the early diagnosis of symptomatic WNV infection. This has recently been documented in patients who presented for diagnosis 8 days after developing WNV symptoms: approximately one-third of patients with acute WNV infection diagnosed were RNA positive and IgM negative [42] . In this early postsymptomatic period, 8% of patients tested positive for both RNA and IgM, similar to the rate of IgM positivity detected by MP-NAT among asymptomatic donors in our studies. Furthermore, the mean viral load among WNV RNA-positive patients in the diagnostic setting was 7.5 ϫ 10 3 copies/mL, which is very similar to that detected for asymptomatic donors by use of MP-NAT [7, 11] . This suggests that the sensitivity of the NAT used in the diagnostic laboratory (expressed by Tilley et al. [42] in plaque-forming units rather than copies/mL) was comparable to that of MP-TMA and that the dynamics of RNA loss and IgM development may be similar in asymptomatic and symptomatic cases. Further study will be needed to corroborate this hypothesis.
Eight transfusion-transmitted cases of WNV infection have been documented since the implementation of MP-NAT in 2003, and in all cases that could be evaluated, transmission resulted from units that were retrospectively found to be RNA positive by ID-NAT and IgM and IgG negative [15, 16, 43] . These clinical surveillance data have generated the current working hypothesis that viremic units that are also positive for WNVspecific antibody are not infectious when transfused. This hypothesis is supported by in vitro and epidemiologic evidence. First, as demonstrated by our evaluation of 27 donors in this study, WNV-specific neutralizing antibody is detectable at approximately the same time as IgM and IgG are first detected and, in the 4 cases described in table 3, persisted throughout the longest intervals of viremia that we observed. Second, no documented transmissions from antibody-positive units occurred during 2003 before the implementation of MP-NAT, despite the likelihood that a large number of RNA-positive, IgM-positive, and IgG-positive units were transfused.
We used our current data on WNV dynamics to estimate the number of antibody-positive blood components with low-level viremia (i.e., blood components in which WNV was detectable only by multiple replicate ID-NAT) that were transfused during 2003-2005. Our calculation is based on the relative durations of the window periods of MP-NAT positivity (6.9 days) and 6-replicate TMA positivity (6.1 days) and on nationally compiled data indicating that at least 1038 WNV-positive donations confirmed by MP-NAT were detected during 2003-2005 [42] . We estimate that at least 917 (1038 ϫ [6.1/6.9]) seropositive units with low-level viremia (i.e., WNV RNA levels below the ID-NAT detection limit) were donated in these 3 years [44] . This likely would have resulted in the transfusion of 1330 WNVpositive components (917 donations ϫ 1.45 components per donation), because such components would not have been detected by MP-NAT and were also unlikely to have been detected by targeted ID-NAT. Because all 7 cases of posttransfusion WNV infection during 2003-2005 were traced to units that were negative for WNV-specific antibody but positive for WNV RNA by single-replicate ID-NAT, this strongly suggests that very lowlevel WNV viremia in the presence of WNV antibody is either not infectious or, if rarely infectious, does not produce clinical symptoms.
Because the potential for transmissions from low-level viremic, antibody-positive units has not been ruled out by statistically powered human transfusion-based look-back studies, the FDA has recommended that donors be deferred from donation for 120 days after detection of WNV RNA [45] . This recommendation was based on the infrequent persistence of RNA beyond day 40 after the index donation and an additional precautionary adjustment to allow for even longer persistence. In this report, we have estimated that 99% of donors with WNV viremia will clear WNV from the blood 50 days after the index donation, with an upper 95% confidence bound of 85 days. We found only 1 donor (0.6%) who failed to clear viremia before the 85-day upper confidence bound (RNA was detectable in this donor for 104 days after the index donation). Our estimates therefore suggest that the 120-day deferral period is a conservative precautionary policy, particularly because all samples with persistent viremia had high titers of WNV-specific neutralizing antibodies present. Combined with the clinical surveillance data discussed above, it is highly unlikely that a blood donation obtained after low-level WNV viremia becomes persistent would be infectious. We conclude that the FDA donor-deferral recommendations probably err on the side of caution and that there is no risk of WNV transmission through transfusion of blood from previously viremic donors who return to donate after their 120-day deferral interval and have blood samples obtained at the second donation that test negative for WNV by MP-NAT.
